TY - JOUR
T1 - Long-term visual outcomes in patients with orbitotemporal neurofibromatosis
AU - Greenwell, Timothy H.
AU - Anderson, Peter J.
AU - Madge, Simon K.
AU - Selva, Dinesh
AU - David, David J.
PY - 2014/4
Y1 - 2014/4
N2 - Background: The study aimed to review the presentation and long-term visual outcomes of patients with orbitotemporal neurofibromatosis. Design: Retrospective case series. Participants: Patients with orbitotemporal neurofibromatosis presenting from 1981 to 2009. Methods: Demographic data, examination findings, causes of vision impairment and interventions performed were recorded for each patient from presentation through subsequent follow-up encounters. Visual impairment was defined as an ipsilateral Snellen acuity of <6/12. Main Outcome Measures: The proportion of patients with visual impairment or enucleation, the rate of new vision loss during follow up; and causes for vision loss or enucleation. Results: Thirty-seven patients (17 female) were included. Median presenting age was 15 years (range 2-45) with an average follow up of 7.4 years (range 0.5-20.3). Visual impairment occurred in 54% of patients at presentation. Causes were amblyopia (13 of 37), optic atrophy (4 of 37), previous enucleation/evisceration (2 of 37), and optic nerve glioma (1 of 37). At presentation, 76% of patients had ptosis, and 51% had strabismus. Thirty-one patients had surgery, with an average of two procedures per patient. At final follow up, 62% had visual impairment. The rate of visual decline was 2% per patient-years. Causes of visual decline were two patients with optic nerve atrophy, one with exposure keratitis and one whose cause was unknown. Five blind patients had enucleation. Conclusions: The first series of orbitotemporal neurofibromatosis to focus on visual outcomes was presented. Vision loss is common, with a high prevalence of amblyopia. Close monitoring from an early age is needed to prevent visual impairment.
AB - Background: The study aimed to review the presentation and long-term visual outcomes of patients with orbitotemporal neurofibromatosis. Design: Retrospective case series. Participants: Patients with orbitotemporal neurofibromatosis presenting from 1981 to 2009. Methods: Demographic data, examination findings, causes of vision impairment and interventions performed were recorded for each patient from presentation through subsequent follow-up encounters. Visual impairment was defined as an ipsilateral Snellen acuity of <6/12. Main Outcome Measures: The proportion of patients with visual impairment or enucleation, the rate of new vision loss during follow up; and causes for vision loss or enucleation. Results: Thirty-seven patients (17 female) were included. Median presenting age was 15 years (range 2-45) with an average follow up of 7.4 years (range 0.5-20.3). Visual impairment occurred in 54% of patients at presentation. Causes were amblyopia (13 of 37), optic atrophy (4 of 37), previous enucleation/evisceration (2 of 37), and optic nerve glioma (1 of 37). At presentation, 76% of patients had ptosis, and 51% had strabismus. Thirty-one patients had surgery, with an average of two procedures per patient. At final follow up, 62% had visual impairment. The rate of visual decline was 2% per patient-years. Causes of visual decline were two patients with optic nerve atrophy, one with exposure keratitis and one whose cause was unknown. Five blind patients had enucleation. Conclusions: The first series of orbitotemporal neurofibromatosis to focus on visual outcomes was presented. Vision loss is common, with a high prevalence of amblyopia. Close monitoring from an early age is needed to prevent visual impairment.
KW - Craniofacial surgery
KW - Neurofibromatosis type 1
KW - Orbitofacial tumours
UR - http://www.scopus.com/inward/record.url?scp=84899087175&partnerID=8YFLogxK
U2 - 10.1111/ceo.12179
DO - 10.1111/ceo.12179
M3 - Article
C2 - 23926960
AN - SCOPUS:84899087175
SN - 1442-6404
VL - 42
SP - 266
EP - 270
JO - Clinical and Experimental Ophthalmology
JF - Clinical and Experimental Ophthalmology
IS - 3
ER -